Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PLAG1
REST API REST API
Homo sapiens
PLAG1 is differentially expressed in 220 experiments: 89 organism parts: liver, pituitary gland, ... (87 more);, 138 disease states: normal, acute myeloid leukemia, ... (136 more);, 70 cell types 350 cell lines 18 compound treatments and 61 other conditions.
Synonyms ZNF912
Orthologs PLAG1 (Bos taurus)   PLAG1_CHICK (Gallus gallus)   ENSGALG00000022130 (Gallus gallus)   plag1 (Danio rerio)   Plag1 (Mus musculus)   Plag1 (Rattus norvegicus)   plag1 (Xenopus laevis)   PLAG1 (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, intracellular, transcription, DNA-dependent, positive regulation of gene expression, metal ion binding, nucleic acid binding, organ growth, multicellular organism growth, nucleus, negative regulation of gene expression, zinc ion binding, prostate gland growth, positive regulation of glial cell proliferation, gland morphogenesis, sequence-specific DNA binding transcription factor activity
UniProt Accession Q6DJT9, A7IT80, A7IT79, B4DLC2
Gene-Disease Assocation SALIVARY GLAND ADENOMA, PLEOMORPHIC
Search EB-eye ENSG00000181690
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-7224, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-6013, E-GEOD-3202
GM15510
2
E-GEOD-19466, E-GEOD-22639
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
H441
2
E-MTAB-62, E-GEOD-16194
HT1080
2
E-GEOD-20089, E-MTAB-37
344 more value(s).


Cell type

studied in E-GEOD-22529, E-TABM-40, E-GEOD-20193, E-GEOD-21668, E-GEOD-20677, ... (39 experiments)

Factor Value U/D Experiments
fibroblast
1
E-GEOD-3204
memory B cell
1
E-GEOD-17186
activated B-cell
1
E-MEXP-2360
spermatid
1
E-TABM-130
CD14+ monocyte
2
1
E-MEXP-1600
plasma cell
1
E-GEOD-6691
64 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-16363, E-GEOD-3678, E-GEOD-5370, ... (49 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-3868
chronic myelogenous leukemia
2
E-GEOD-5550, E-MTAB-62
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
embryonal rhabdomyosarcoma
2
E-MTAB-62, E-MEXP-121
uterine fibroid
2
E-MTAB-62, E-GEOD-2724
cololrectal tumor
1
E-MTAB-62
132 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-15811, E-GEOD-5099, ... (13 experiments)

Factor Value U/D Experiments
none
4
E-GEOD-995, E-GEOD-412, E-TABM-782, E-MEXP-1958
control - keratinocyte growth factor
1
E-GEOD-7216
lipopolysaccharide
1
E-MEXP-1958
4OH-tamoxifen
1
E-GEOD-2292
resveratrol
1
E-TABM-782
interleukin-22 (Homo sapiens)
1
E-GEOD-7216
12 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
75
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-2724, E-GEOD-18005, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-GEOD-12773, E-GEOD-20504, E-MEXP-1446, E-GEOD-9764, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-TABM-666, ... (17 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-5824, E-GEOD-1657, E-GEOD-1460, ... (6 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-2018, E-GEOD-1926

Treatment
studied in E-MEXP-973, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271

Processing time: 0.353 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM